StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
7140.T$816.00-2.72%
Fair $816.00+0.0%

7140.T

Petgo Corporation

Healthcare / Medical Care FacilitiesTokyo

$816.00

-23.00 (-2.72%)

Fairly Valued+0.0%Fair Value $816.00Fund rank 22/100 · Data gapFallback financials|
SA 36/D
F-Score: 3/9
Declining Revenue

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 16%

FCF escenarios

weak_data · normalized FCF $86.9M · quality 33.7/100

Data gap 22/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 10/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

36/100

D

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. Revenue has declined for 2 consecutive years
Thesis & Journal · 7140.TLocal privado en este navegador · Petgo Corporation
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$1.5B

P/E

11.9x

↓

EV/EBITDA

6.0x

↓

ROE

10.5%

↑

Gross Margin

31.1%

↓

Debt/Equity

0.91

↑
52-Week Range$816
$723$980

TradingView lightweight chart

7140.T price, volumen y niveles de valoración

Último $822.00Periodo -17.4%
Fair value: $816.00

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-2.2%

FCF CAGR

—

FCF margin

1.0%

FCF / Net income

0.68x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $9.03B · net income $128.3M · FCF $86.9M

2022-FY → 2025-FY

Gross margin

31.1%+4.4% pts

Operating margin

2.5%+0.8% pts

Net margin

1.4%+0.3% pts

FCF margin

1.0%+3.3% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$9.03B$9.03B$9.91B$10.03B$9.65B
Net Income$128.3M$128.3M$172.3M$153.3M$105.1M
EBITDA$230.0M$230.0M$263.8M$256.1M$175.2M
EPS68.8568.8588.2084.2487.88
Gross Margin31.1%31.1%27.9%28.4%26.7%
Operating Margin2.5%2.5%2.5%2.4%1.7%
Net Margin1.4%1.4%1.7%1.5%1.1%
Balance Sheet
Debt/Equity0.910.910.680.931.94
Current Ratio1.421.42———
Cash Flow
Free Cash Flow$86.9M$86.9M$160.2M$-256.0M$-227.0M
Returns
ROE10.5%10.5%15.3%16.4%23.1%
Valuation
P/E11.8511.8510.2417.83—
EV/EBITDA5.955.956.1710.79—
P/B1.241.241.572.92—
Growth & Yield
Revenue Growth-8.8%-8.8%-1.2%3.9%—
EPS Growth-21.9%-21.9%4.7%-4.1%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

1.7%

fácil

EPS terminal req.

$72.41

Spread vs growth

-23.6%

5Y implied EPS CAGR

4.9%

fácil

EPS terminal req.

$87.61

Spread vs growth

-26.9%

10Y implied EPS CAGR

7.4%

razonable

EPS terminal req.

$141.10

Spread vs growth

-29.4%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +7.2%

Total return

+7.2%

Start / end P/E

8.7x → 11.9x

EPS bridge

88.20 → 68.85

Residual

-8.2%

EPS growth-21.9%
Multiple rerating+37.3%
Dividend+0.0%
Residual / FX / buybacks / cross-term-8.2%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.